Regulatory & Industry
| 4 min read
Two new FDA approvals, a CRISPR program discontinued, discussions of a major merger, and more led the news this week.
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 3 min read
Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
| 4 min read
Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week.
| 5 min read
Wobble Genomics is using long-read RNA sequencing to reveal the molecular signals that determine whether a cancer treatment will work.
| 4 min read
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
| 3 min read
The science being built right now in discovery labs is what acquirers are already looking for.
| 2 min read
The deal brings a first-in-class anti-CD122 antibody with early clinical validation in vitiligo and celiac disease into argenx's pipeline.
| 2 min read
The expanded service brings 10x Genomics-powered single-cell RNA sequencing to Novogene Europe's Cambridge Omics Centre, providing UK researchers with local access to end-to-end workflows and bioinformatics support.
| 5 min read
The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing.
| 3 min read
The MHRA-led sandbox will generate real-world evidence on AI tools that could improve medicines safety, reduce late-stage failures, and accelerate drug development.
| 5 min read
The FDA announced interest in advancing drug repurposing programs across a wide variety of conditions, though challenges remain.
